Emory Healthcare Validates Microbot Medical’s Robotic System in Key Endovascular Procedures

Event summary

  • Emory Healthcare completed robotic peripheral endovascular procedures using Microbot Medical’s LIBERTY® System, including first robotic PAE for BPH and Y-90 radioembolization mapping for liver cancer.
  • Microbot Medical plans Full Market Release of LIBERTY System at Society of Interventional Radiology conference in April 2026.
  • LIBERTY System is FDA-cleared for single-use, remotely operated robotic endovascular procedures.
  • Emory’s interventional radiologists highlighted precision and efficiency gains in treating BPH and liver cancer.

The big picture

Microbot Medical’s LIBERTY System is positioning itself as a disruptive force in endovascular care, akin to how robotic-assisted prostatectomy transformed prostate cancer treatment. Emory Healthcare’s successful adoption of the system for BPH and liver cancer procedures signals potential for broader market acceptance. The upcoming Full Market Release at the Society of Interventional Radiology conference could further solidify its role in precision endovascular navigation.

What we're watching

Adoption Pace
How quickly Emory Healthcare and other institutions will integrate LIBERTY System into standard endovascular procedures.
Market Expansion
Whether Microbot Medical can replicate this success in other medical centers beyond Emory Healthcare.
Regulatory Approval
The pace at which additional FDA clearances or approvals could accelerate LIBERTY System’s market penetration.